Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: To generate an animal model exhibiting symptoms similar to those of human amyotrophic lateral sclerosis and/or human frontotemporal lobar degeneration. An animal model exhibiting symptoms similar to those of human amyotrophic lateral sclerosis and/or human frontotemporal lobar degeneration can be produced by means of generating a mutation in a vertebrate so that expression of a mutant protein with a substitution of tyrosine for alanine at a position corresponding to position 382 of SEQ ID NO. 1 or a mutant protein with a substitution of cysteine for glycine at a position corresponding to position 348 of SEQ ID NO. 1 is regulated by an endogenous TDP-43 gene promoter in at least one allele of an endogenous TDP-43 gene of the vertebrate.

Abstract: A therapeutic and/or preventive agent for inner ear disorders comprising an IL-6 antagonist, preferably an anti-IL-6R antibody, as an active ingredient.

Abstract: Problems to be Solved Methods for enhancing survival and/or proliferation of neural stem cells and pharmaceutical compositions containing neural stem cells prepared by such methods, together with methods for assaying factors enhancing survival and/or proliferation of neural stem cells and methods for screening for such factors. Means for Solving the Problem Either Galectin-1 is overexpressed in neural stem cells or neural stem cells are cultured in a liquid medium containing Galectin-1. Pharmaceutical compositions containing Galectin-1-overexpressing neural stem cells and pharmaceutical composition containing Galectin-1, prepared by the aforementioned methods, improve higher cerebral functions damaged by cerebral ischemia.